AP2000001735A0 - Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor. - Google Patents

Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor.

Info

Publication number
AP2000001735A0
AP2000001735A0 APAP/P/2000/001735A AP2000001735A AP2000001735A0 AP 2000001735 A0 AP2000001735 A0 AP 2000001735A0 AP 2000001735 A AP2000001735 A AP 2000001735A AP 2000001735 A0 AP2000001735 A0 AP 2000001735A0
Authority
AP
ARIPO
Prior art keywords
treatment
alpha
diabetes
glucocidase
inhibitor
Prior art date
Application number
APAP/P/2000/001735A
Inventor
Robin Edwin Buckingham
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AP2000001735A0 publication Critical patent/AP2000001735A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmacuetically acceptable amount of an insulin sensitiser, an insulin secretagogueand an alpha glucosidase inhibitor antihyperglycaemic agent, to amammal in need thereof; and composition for use in such method.
APAP/P/2000/001735A 1997-07-18 2000-01-14 Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor. AP2000001735A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment
PCT/GB1998/002112 WO1999003478A1 (en) 1997-07-18 1998-07-16 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor

Publications (1)

Publication Number Publication Date
AP2000001735A0 true AP2000001735A0 (en) 2000-01-16

Family

ID=10816170

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2000/001735A AP2000001735A0 (en) 1997-07-18 2000-01-14 Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor.

Country Status (27)

Country Link
EP (1) EP1001784A1 (en)
JP (1) JP2001510160A (en)
KR (1) KR20010021952A (en)
CN (1) CN1263467A (en)
AP (1) AP2000001735A0 (en)
AR (2) AR016350A1 (en)
AU (1) AU8449098A (en)
BG (1) BG104062A (en)
BR (1) BR9810292A (en)
CA (1) CA2297133A1 (en)
CO (1) CO4940489A1 (en)
DZ (1) DZ2563A1 (en)
EA (1) EA200000140A1 (en)
GB (1) GB9715298D0 (en)
HU (1) HUP0003626A3 (en)
ID (1) ID23804A (en)
IL (1) IL133907A0 (en)
MA (1) MA24608A1 (en)
NO (1) NO20000230D0 (en)
OA (1) OA11312A (en)
PE (1) PE99499A1 (en)
PL (1) PL338140A1 (en)
SK (1) SK612000A3 (en)
TR (1) TR200000133T2 (en)
UY (1) UY25101A1 (en)
WO (1) WO1999003478A1 (en)
ZA (1) ZA986364B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ES2291210T3 (en) * 1999-06-21 2008-03-01 Eli Lilly And Company SYNERGISTIC USE OF THIAZOLIDINDIONAS WITH PEPTIDO-1 TYPE GLUCAGONA AND ITS AGONISTS TO TREAT NON-INSULIN-DEPENDENT DIABETES.
BRPI0107715B8 (en) * 2000-01-21 2021-05-25 Novartis Ag pharmaceutical product comprising an inhibitor of dipeptidyl peptidase-iv and metformin, as well as uses of said pharmaceutical product and inhibitor of dipeptidyl peptidase-iv
EP1295609A4 (en) * 2000-02-24 2004-11-03 Takeda Chemical Industries Ltd Drugs containing combined active ingredients
JP4917712B2 (en) * 2000-02-24 2012-04-18 武田薬品工業株式会社 Concomitant medication
JP4633329B2 (en) 2001-01-12 2011-02-16 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド Spaced drug delivery system
FR2832930A1 (en) * 2001-12-03 2003-06-06 Lipha PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES
NZ546337A (en) 2003-10-31 2009-03-31 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80
CN101103993B (en) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 Hypoglycemic medicine composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2101866T3 (en) * 1991-08-26 1997-07-16 Upjohn Co LIQUID FOOD PRODUCT CONTAINING 3-GUANIDINOPROPIONIC ACID.
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
PL338140A1 (en) 2000-09-25
SK612000A3 (en) 2000-07-11
ZA986364B (en) 2000-01-17
CN1263467A (en) 2000-08-16
NO20000230L (en) 2000-01-17
AR016350A1 (en) 2001-07-04
GB9715298D0 (en) 1997-09-24
WO1999003478A1 (en) 1999-01-28
UY25101A1 (en) 2000-12-29
AR019724A2 (en) 2002-03-13
HUP0003626A3 (en) 2001-12-28
BG104062A (en) 2000-11-30
DZ2563A1 (en) 2003-02-15
TR200000133T2 (en) 2000-09-21
CO4940489A1 (en) 2000-07-24
ID23804A (en) 2000-05-11
EP1001784A1 (en) 2000-05-24
AU8449098A (en) 1999-02-10
MA24608A1 (en) 1999-04-01
NO20000230D0 (en) 2000-01-17
IL133907A0 (en) 2001-04-30
PE99499A1 (en) 1999-12-18
KR20010021952A (en) 2001-03-15
BR9810292A (en) 2000-09-19
CA2297133A1 (en) 1999-01-28
OA11312A (en) 2003-10-24
JP2001510160A (en) 2001-07-31
HUP0003626A2 (en) 2001-05-28
EA200000140A1 (en) 2000-06-26

Similar Documents

Publication Publication Date Title
AP2002002703A0 (en) Combinations of depeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diadetes mellitus.
CA2294582A1 (en) Treatment of diabetes with thiazolidinedione and metformin
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
MY124695A (en) Novel composition and use.
AP2001002291A0 (en) Novel method of treatment.
AP2000001735A0 (en) Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor.
TR199903095T2 (en) Treatment of diabetes with rosiglitazone and insulin.
AP9901720A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
MY125855A (en) Treatment of diabetes with a thiazolidinedione and sulphonylurea
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
TR200101336T2 (en) Combinations with a beta-agonist and another antidiabetic agent
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
IL143088A0 (en) A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method
HUP0002569A2 (en) Pharmaceutical compositions for treatment of diabetes containing thiazolidinedione and alpha-glucosidase inhibitors
ECSP982542A (en) NEW METHOD OF TREATMENT III
HUP0002668A2 (en) Treatment of diabetes with thiazolidinedione and metformin
AP2000001787A0 (en) Use of thiazolidinediones for the treatment of hyperglycaemia.
ECSP982534A (en) NEW METHOD OF TREATMENT
HUP0002669A2 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
ECSP982593A (en) NEW METHOD OF TREATMENT VI
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
ECSP982535A (en) NEW TREATMENT METHOD (I)